Oric Pharmaceuticals (ORIC) Cash from Investing Activities (2019 - 2026)

Oric Pharmaceuticals' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$18.0 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 180.07% year-over-year to -$18.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$188.5 million (down 277.03% YoY) and the FY2025 annual result came in at -$148.0 million, down 768.7% from the prior year.
• Cash from Investing Activities was -$18.0 million for Q1 2026 at Oric Pharmaceuticals, down from $17.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $42.7 million in Q4 2024 and bottomed at -$110.5 million in Q3 2025.
• A 5-year average of -$17.4 million and a median of -$685000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 7962.68% — and 2023, when it plunged 8342.48%.
• Oric Pharmaceuticals' Cash from Investing Activities stood at $28.3 million in 2022, then retreated by 25.93% to $21.0 million in 2023, then soared by 103.48% to $42.7 million in 2024, then tumbled by 60.18% to $17.0 million in 2025, then tumbled by 205.83% to -$18.0 million in 2026.
• Business Quant data shows ORIC's Cash from Investing Activities at -$18.0 million in Q1 2026, $17.0 million in Q4 2025, and -$110.5 million in Q3 2025.